Skip to content

A study to assess the benefits chemotherapy given before the surgery-in patients underwent operation for retroperitoneal Sarcoma a cancer type of posterior abdominal wall tumors.

Analysis of outcomes of neoadjuvant chemotherapy in resectable retroperitoneal sarcomas. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097805
Enrollment
207
Registered
2025-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C480- Malignant neoplasm of retroperitoneum

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or above 2. Histologically confirmed liposarcomas and leiomyosarcomas presenting initially to this institutewithout previous treatment- except for NACT. 3. Resectable tumors

Exclusion criteria

Exclusion criteria: 1. Recurrent cases 2. Preoperative RT

Design outcomes

Primary

MeasureTime frame
1. To evaluate difference inoverall survival(OS) in patients undergoing upfront surgery and NACT followed by surgery in resectable retroperitoneal liposarcomas and leiomyosarcomasTimepoint: 3 monthly for first 2 years after surgery then 6 monthly for next 3 years

Secondary

MeasureTime frame
1.To study recurrence ratesin patients undergoing upfront surgery vs NACT followed by surgery in resectable retroperitoneal liposarcomas and leiomyosarcomasTimepoint: 3 monthly for first 2 years after surgery then 6 monthly for next 3 years;2. Complete resection rates in the two groupsTimepoint: 3 monthly for first 2 years after surgery then 6 monthly for next 3 years;3. Tumour downstaging rates in with NACTTimepoint: 3 monthly for first 2 years after surgery then 6 monthly for next 3 years;3. Pathological response ratem recurrence patterns and post operative morbidity and mortality in the two groupsTimepoint: 3 monthly for first 2 years after surgery then 6 monthly for next 3 years

Countries

India

Contacts

Public ContactDr Shraddha Padkar

Tata memorial Hospital, Mumbai

lavanyalakshmi26@gmail.com9820074818

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026